Skip to content

NCBIO Blog

Stay up to date with the latest from NCBIO

Recent Posts

BIO: How the PASTEUR Act would support antibiotic R&D

June 22, 2021

The PASTEUR Act, legislation designed to make research and development of new antibiotics economically viable, was reintroduced in Congress last week with bipartisan support. Here’s what it would do and why it matters. Antimicrobial resistance is a big problem. AMR occurs when bacteria, viruses, fungi and parasites no longer respond to antibiotics. If we don’t…

Read More

Government price fixing for U.S. medicines will cost lives, jobs, innovation

May 13, 2021

Legislation like H.R. 3 that fixes prices for prescription medicines would limit patients’ access to new treatments while doing nothing to lower prices at the pharmacy counter.

Read More

Vaccine patent waiver breaks faith with American companies, stifles innovation

May 13, 2021

NCBIO is extremely disappointed that the Biden administration has chosen to support waiving critical intellectual property protections for U.S. COVID-19 vaccines. This decision, known as a TRIPS waiver, breaks faith with American innovators, punishes the ingenuity of our life sciences industry and will delay the equitable delivery of COVID vaccines to people around the globe.    …

Read More

BIO: Why the TRIPS waiver wouldn’t work

April 20, 2021

BIO President and CEO Dr. Michelle McMurry-Heath sent a letter April 19 to U.S. Trade Representative Ambassador Katherine Tai to explain why the WTO’s proposed “TRIPS waiver” would have global health and economic consequences as the pandemic rages on.

Read More

Executive order on drug prices does no favors for NC patients, hospitals

November 25, 2020

A new executive order that slashes Medicare payments to hospitals and physicians for certain medicines will hurt patients’ access to care and financially stress already overburdened hospitals and innovation-based pharmaceutical companies

Read More